Literature DB >> 17088168

A 1-year follow-up study of chest-pain patients with and without panic disorder.

Toril Dammen1, Christine Bull Bringager, Harald Arnesen, Oivind Ekeberg, Svein Friis.   

Abstract

OBJECTIVE: The aims of this study were to (a) study the persistence of panic disorder (PD); (b) investigate the association between PD at baseline and outcome [chest pain, psychiatric morbidity, health care utilization, suicidal thoughts, work impairment and health-related quality of life (HRQOL)]; (c) study the course of pain, distress, symptom attribution and HRQOL; and (d) describe treatment and perceived treatment needs of patients with PD.
METHOD: A 1-year follow-up study of 199 chest-pain patients referred to cardiac outpatient investigation was completed. Assessments included Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (SCID), Short-Form McGill Pain Questionnaire, Symptom Checklist-90-Revised, the Illness Attitude Scales, the 36-item Short-Form Health Survey and a chest-pain questionnaire.
RESULTS: At follow-up, 57 of the 153 patients reassessed with the SCID suffered from PD. Forty-three of the 55 patients (78%) who were diagnosed with PD at baseline still suffered from PD at follow-up. PD at baseline was associated with pain persistence, psychiatric morbidity (current major depression, pain disorder and simple phobia), significantly higher scores on psychological distress, hypochondriasis, negative outcome expectation, lower scores on seven of the eight dimensions of HRQOL and more general practitioner consultations. Only 6% of the patients with PD used effective treatment, and 3% reported a treatment need at follow-up.
CONCLUSION: Despite chronic distress and impairment, we found significant undertreatment of PD, which needs to be addressed in future studies.

Entities:  

Mesh:

Year:  2006        PMID: 17088168     DOI: 10.1016/j.genhosppsych.2006.08.005

Source DB:  PubMed          Journal:  Gen Hosp Psychiatry        ISSN: 0163-8343            Impact factor:   3.238


  7 in total

Review 1.  Quality of life in panic disorder: looking beyond symptom remission.

Authors:  Julia Davidoff; Scott Christensen; David N Khalili; Jaidyn Nguyen; Waguih William IsHak
Journal:  Qual Life Res       Date:  2011-09-21       Impact factor: 4.147

2.  Quality of Life in Patients with Coronary Artery Disease and Panic Disorder: A Comparative Study.

Authors:  Shruti Srivastava; Skand Shekhar; Manjeet Singh Bhatia; Shridhar Dwivedi
Journal:  Oman Med J       Date:  2017-01

3.  Chest pain and its importance in patients with panic disorder: an updated literature review.

Authors:  David A Katerndahl
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

4.  The prevalence of non-cardiac chest pain (NCCP) using emergency department (ED) data: a Northern Ireland based study.

Authors:  Orla McDevitt-Petrovic; Karen Kirby; Mark Shevlin
Journal:  BMC Health Serv Res       Date:  2017-08-09       Impact factor: 2.655

5.  Anxiety disorders in patients with noncardiac chest pain: association with health-related quality of life and chest pain severity.

Authors:  Stéphanie Hamel; Isabelle Denis; Stéphane Turcotte; Richard Fleet; Patrick Archambault; Clermont E Dionne; Guillaume Foldes-Busque
Journal:  Health Qual Life Outcomes       Date:  2022-01-10       Impact factor: 3.186

6.  Effectiveness of Internet-Based Cognitive Behavioral Therapy With Telephone Support for Noncardiac Chest Pain: Randomized Controlled Trial.

Authors:  Terje Thesen; Joseph A Himle; Egil W Martinsen; Liv T Walseth; Frode Thorup; Frode Gallefoss; Egil Jonsbu
Journal:  J Med Internet Res       Date:  2022-01-24       Impact factor: 5.428

7.  A prospective cohort study to refine and validate the Panic Screening Score for identifying panic attacks associated with unexplained chest pain in the emergency department.

Authors:  Guillaume Foldes-Busque; Isabelle Denis; Julien Poitras; Richard P Fleet; Patrick Archambault; Clermont E Dionne
Journal:  BMJ Open       Date:  2013-10-25       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.